Recall Active for Bevacizumab

A defective drug delivery system has prompted AmEx Pharmacy to issue a recall for 249 syringes of bevacizumab 1.25 mg/0.05 mL 31G MJ syringe intravitreal injection. The recall is included in the May 8, 2019, US Food and Drug Administration (FDA) Enforcement Report. 

The recall affects syringes repackaged by AmEx Pharmacy on February 12, 2019, from lot 190212AB (BUD 5/13/19). The syringes were distributed throughout the United States.  

AmEx Pharmacy voluntarily issued the recall April 19, 2019. On May 7, 2019, the FDA designated it Class II. The classification suggests use of the product could cause temporary or medically reversible adverse health consequences. Although the likelihood is remote, a possibility of serious harm also exists. 

Bevacizumab is a biologic medication used in the treatment of numerous cancers, including kidney, cervical, ovarian, colon, and rectal cancer.

—Jolynn Tumolo